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Introduction
  Dyslipidemia refers to elevated total or low-density lipoprotein 
(LDL) cholesterol levels, or reduced high-density lipoprotein 
(HDL) cholesterol level due to impaired lipoprotein metabo-
lism. According to the guidelines of the Adult Treatment Panel 
III of the National Cholesterol Education Program and 2013 
guidelines of the American College of Cardiology (ACC)/
American Heart Association (AHA), decreasing blood LDL 
cholesterol is key to the management of dyslipidemia.[1,2] The 
treatment of dyslipidemia includes therapeutic lifestyle changes, 
such as weight management, limited intake of saturated fats and 
cholesterol, and drug therapy. Aggressive actions to reduce LDL 
cholesterol are recommended for patients at a higher risk of de-
veloping cardiovascular disease (CVD).[3,4]
  Statins are currently used as first-line therapy for dyslipidemia 
because they have clear prognostic benefits, such as decreasing 
CVD incidence and increasing survival rate by lowering LDL 
cholesterol, with relatively low side effects.[5] Atorvastatin is 
Atorvastatin and ezetimibe are frequently co-administered to treat patients with dyslipidemia for 
the purpose of low-density lipoprotein cholesterol control. However, pharmacokinetic (PK) drug 
interaction between atorvastatin and ezetimibe has not been evaluated in Korean population. The 
aim of this study was to investigate PK drug interaction between two drugs in healthy Korean vol-
unteers. An open-label, randomized, multiple-dose, three-treatment, three-period, Williams design 
crossover study was conducted in 36 healthy male subjects. During each period, the subjects re-
ceived one of the following three treatments for seven days: atorvastatin 40 mg, ezetimibe 10 mg, or 
a combination of both. Blood samples were collected up to 96 h after dosing, and PK parameters of 
atorvastatin, 2-hydroxyatorvastatin, total ezetimibe (free ezetimibe + ezetimibe-glucuronide), and 
free ezetimibe were estimated by non-compartmental analysis in 32 subjects who completed the 
study. Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) of the maximum plasma 
concentration (Cmax,ss) and the area under the curve within a dosing interval at steady state (AUCτ,ss) 
of atorvastatin when administered with and without ezetimibe were 1.1087 (0.9799–1.2544) and 
1.1154 (1.0079–1.2344), respectively. The corresponding values for total ezetimibe were 1.0005 
(0.9227–1.0849) and 1.0176 (0.9465–1.0941). There was no clinically significant change in safety 
assessment related to either atorvastatin or ezetimibe. Co-administration of atorvastatin and ezeti-
mibe showed similar PK and safety profile compared with each drug alone. The PK interaction be-
tween two drugs was not clinically significant in healthy Korean volunteers.
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a well-known statin that inhibits cholesterol synthesis in the 
liver by competitively inhibiting 3-hydroxy-3-methylglutaryl 
coenzyme A reductase.[6] However, additional measures are 
necessary when aggressive statin therapy does not adequately 
decrease LDL cholesterol or when statin therapy is discontin-
ued due to side effects. In such cases, the ACC/AHA guidelines 
recommend the use of a combination of low-dose statin and 
another non-statin lipid-modifying agent.[2]
  Ezetimibe is a lipid-modifying agent that inhibits the absorp-
tion of cholesterol present in food or bile by blocking the Nie-
mann–Pick C1-like 1 protein in the villi of the small intestine. 
[7,8] A previous study, which investigated patients with CVD or 
diabetes, found that ezetimibe-statin combination therapy was 
more effective than monotherapy with a high-dose statin at low-
ering LDL cholesterol and other lipid parameters.[9,10] Owing 
to such synergistic advantages and low side effects, ezetimibe 
is frequently co-administered with statins in clinical practice. 
Further, it is necessary to develop a fixed-dose combination to 
improve medication compliance; however, the pharmacokinetic 
(PK) drug interaction between atorvastatin and ezetimibe in 
Korean population has not been evaluated. Therefore, this study 
was conducted to investigate the PK interaction between ator-
vastatin 40 mg and ezetimibe 10 mg in healthy Korean volun-
teers.
Methods 
  This study was conducted at the Clinical Trials Center, Yonsei 
University Severance Hospital (Seoul, Korea) in accordance 
with the Declaration of Helsinki and the guidelines of the Ko-
rean Good Clinical Practices after approval of the protocol by 
the Institutional Review Board of Severance Hospital (approval 
number: 4-2014-0742). The study was registered at ClinicalTri-
als.gov with the identifier number NCT02288338. All subjects 
fully understood the objectives, procedures, risks, and benefits 
of the study before providing their written informed consents 
prior to enrollment.
Subjects
  Healthy Korean volunteers aged 19–45 years with body mass 
index (BMI) of 18.5–25 kg/m2 and weight > 55 (for males) or 
> 50 kg (for females) were screened for enrollment based on 
medical history, physical examination, and the results of clinical 
laboratory tests (hematology, blood chemistry, serologic test, 
urinalysis, and urine drug test). Subjects with a history of gas-
trointestinal disease or surgery that could affect the absorption 
of the investigational products (IPs) or those allergic to the IPs 
were excluded. Additionally, subjects with a history of genetic 
disorders, such as galactose intolerance or Lapp lactase defi-
ciency, were excluded.
Study Design and Procedures
  This was a randomized, open-label, multiple-dose, three-
treatment, three-period, Williams design crossover study (Fig. 
1). The IPs were atorvastatin calcium (40 mg, Lipitor®, Pfizer 
Korea Ltd.) and ezetimibe (10 mg, Ezetrol®, MSD Korea Ltd.). 
All subjects were randomly assigned to one of the following 
six treatment sequences: ABC, ACB, BCA, BAC, CAB, or CBA 
with an 11-day washout period between treatments A, B, and 
C. The treatment regimens were once daily administrations of 
atorvastatin 40 mg (treatment A), ezetimibe 10 mg (treatment 
B), or co-administration of atorvastatin 40 mg and ezetimibe 10 
mg (treatment C) for seven days. The subjects visited the outpa-
tient clinic at 8 am each morning, and were orally administered 
the assigned IP with 240 mL water at the fasted state for the first 
six days of each period (D1~D6, D18~D23, and D35~D40). 
They were hospitalized in the afternoon on the 6th day of each 
period for intensive PK sampling and safety assessment. After 
overnight fasting, the 7th dose of the IP was orally administered 
with 240 mL water; all subjects were prohibited from drinking 
water for 1 h before and after IP administration. After fasting 
for 4 h post-dose, a standard meal (700–800 kcal and 5–25% fat) 
was served to all subjects at 4 and 10 h after dosing.
Blood Sampling and Determination of Drug Concentra-
tions
  Serial blood samples were collected in heparinized tubes at 0 
(pre-dose), 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 
36, and 48 h after the last IP administration in each period. 
Blood samples were also collected to estimate trough plasma 
concentration at 0 h (pre-dose) before the 5th and the 6th doses. 
For treatment groups B and C, blood samples were additionally 
collected at 72 and 96 h after the last dosing for the determina-
tion of ezetimibe concentrations. The samples were centrifuged 
(1,800 g, 4˚C, 10 min), and the supernatants were separated and 
stored at -70˚C until the analysis of drug concentrations.
  Plasma concentrations of atorvastatin, 2-hydroxyatorvastatin, 
total ezetimibe (free ezetimibe + ezetimibe-glucuronide), and 
Jungsin Park, et al.
Figure 1. Study design; treatment A, atorvastatin 40 mg once daily for 
seven days; treatment B, ezetimibe 10 mg once daily for seven days; 
treatment C, co-administration of atorvastatin 40 mg and ezetimibe 10 
mg once daily for seven days.
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free ezetimibe were measured by liquid chromatography (Shi-
madzu Prominence LC, Shimadzu, Kyoto, Japan) coupled with 
tandem mass spectrometry (API 5000, AB Sciex, Washington 
D.C., USA) based on validated analytical procedures adopted by 
the Korean Ministry of Food and Drug Safety. For atorvastatin 
and its metabolite (2-hydroxyatorvastatin), calibration curves 
were linear in the range of 0.2–300 ng/mL (correlation coef-
ficient, r>0.9950) with the lower limit of quantification (LLOQ) 
as 0.2 ng/mL. The assay ranges of free ezetimibe and total ezeti-
mibe were 0.2–200 and 0.5–500 ng/mL, respectively (r>0.9950) 
with the LLOQ as 0.2 and 0.5 ng/mL, respectively. The accuracy 
of the assay was within the range of 98.8–103.7% for atorvas-
tatin and its metabolite, 95.0–105.9% for free ezetimibe, and 
90.8–100.4% for total ezetimibe; the precision coefficients of 
variation were <6.9% for all analytes.
Pharmacokinetic Analysis
  Non-compartmental analysis was performed using WinNon-
lin® Version 6.3 (Pharsight, Mountain View, CA, USA) to deter-
mine the following PK parameters of atorvastatin, 2-hydroxya-
torvastatin, free ezetimibe, and total ezetimibe: the maximum 
plasma concentration at steady state (Cmax,ss), time to reach Cmax 
(Tmax,ss), area under the concentration-time curve within a dos-
ing interval at steady state (AUCτ,ss), AUC from dosing time 
extrapolated to infinity at steady state (AUCinf,ss), terminal elimi-
nation half-life (t1/2), apparent clearance (CLss/F), and apparent 
volume of distribution (Vdss/F). Plasma drug concentration-
time profiles are presented in linear and log-transformed scales. 
Cmax,ss and Tmax,ss were measured, and AUC was calculated by us-
ing the linear trapezoidal rule. The t1/2 was calculated from the 
ratio of the natural logarithm of 2 and terminal elimination rate 
constant.
Safety Assessment
  Safety was evaluated by monitoring adverse events (AEs), vital 
signs, physical examination, clinical laboratory tests (hematolo-
gy, blood chemistry, urinalysis), and 12-lead electrocardiogram 
(ECG) throughout the study. All AEs reported by the subjects 
or observed by the investigators were recorded and analyzed to 
facilitate causality assessment.
Statistical Analysis
  Descriptive statistics were used to summarize baseline demo-
graphics, such as age, weight, height, and BMI. PK parameters 
and safety profiles were also evaluated using descriptive statis-
tics. All statistical analyses were conducted by using SAS version 
9.2 (SAS institute, Inc, Cary, NC, USA). Primary PK endpoints 
(AUCτ,ss and Cmax,ss) were log-transformed to develop a mixed 
effects model with period, sequence, and treatment as fixed 
effects and subjects nested within the sequence as a random 
effect. Geometric mean ratios (GMRs) with 90% confidence 
intervals (CIs) of the primary PK parameters between two treat-
ment groups (C vs A, or C vs B) were estimated to evaluate PK 
drug interactions. 
Results
Study Subjects
  Of the 36 subjects enrolled in this study, 32 subjects completed 
all procedures and provided blood samples for PK analysis; 
three subjects discontinued the study in the 1st period, and one 
subject dropped out in the 3rd period due to personal requests. 
All enrolled subjects were male. The demographics of the sub-
jects in each treatment sequence are presented in Table 1.
Pharmacokinetics
  The mean plasma concentration-time profiles of atorvas-
tatin and 2-hydroxyatorvastatin with or without ezetimibe co-
administration are shown in Figure 2, and the calculated PK 
parameters are summarized in Table 2. The PK profiles of ator-
vastatin and its metabolite with or without ezetimibe co-admin-
istration were similar; their exposures, expressed as Cmax,ss and 
AUCτ,ss, were not significantly different regardless of ezetimibe 
co-administration. GMRs with 90% CIs of Cmax,ss and AUCτ,ss 
Atorvastatin and ezetimibe interaction
Table 1. Demographic characteristics of each treatment sequence
BMI, body mass index. Treatment A, atorvastatin 40 mg once daily for seven days; treatment B, ezetimibe 10 mg once daily for seven days; treat-
ment C, co-administration of atorvastatin 40 mg and ezetimibe 10 mg once daily for seven days.
Demographic 
Variable
Treatment Sequence (Mean±Standard deviation)
Total
(N=36)ABC
(N=6)
BCA
(N=6)
CAB
(N=6)
ACB
(N=6)
BAC
(N=6)
CBA
(N=6)
Age (years) 29.2±8.6 30.0±7.8 23.3±2.7 27.5±5.5 32.2±5.3 31.8±8.1 29.0±6.9
Weight (kg) 69.8±6.4 68.3±6.5 68.0±4.8 74.0±6.8 66.5±7.2 62.0±5.3 68.1±6.8
Height (cm) 173.9±7.1 174.1±4.6 176.3±5.6 177.3±4.8 176.3±6.5 169.7±3.2 174.6±5.6
BMI (kg/m2) 23.0±1.6 22.5±2.3 21.8±1.1 23.5±1.5 21.3±2.0 21.5±1.5 22.3±1.8
Sex, N (%)
Male 6 (100.0) 6 (100.0) 6 (100.0) 6 (100.0) 6 (100.0) 6 (100.0) 36 (100.0)
Female 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
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Figure 2. Plasma concentration-time profiles of atorvastatin with or without ezetimibe at steady state plotted using (a) linear and (b) log-linear scales, 
and of 2-hydroxyatorvastatin (c) linear and (d) log-linear scales.
Table 2. Pharmacokinetic parameters of atorvastatin and 2-hydroxyatorvastatin
*Median (min-max). GMR, geometric mean ratio; CI, confidence interval. Treatment A, atorvastatin 40 mg once daily for seven days; treatment C, 
co-administration of atorvastatin 40 mg and ezetimibe 10 mg once daily for seven days. Tmax, time to reach maximum plasma concentration; Cmax,ss, 
maximum plasma concentration at steady state; AUCτ,ss, area under the plasma concentration-time curve within a dosing interval at steady state; 
AUCinf,ss, area under the plasma concentration-time curve from dosing time extrapolated to infinity at steady state; t1/2, elimination half-life; CLss/F, 
apparent clearance; Vdss/F, apparent volume of distribution.
Parameters
Atorvastatin 2-hydroxyatorvastatin
Treatment A Treatment C GMR [90% CI] Treatment A Treatment C GMR [90% CI]
N 33 33 33 33 33 33
Tmax (h)* 0.50 (0.25−3.00) 0.50 (0.25−3.00) 1.50 (0.50−4.00) 1.50 (0.50−4.00)
Cmax,ss (ng/mL) 27.54±8.90 32.67±19.15
1.1087
[0.9799–1.2544]
18.56±9.46 21.67±12.95
1.1147
[1.0197–1.2184]
AUCτ,ss (ng·h/mL) 90.38±33.57 107.75±71.74
1.1154
[1.0079–1.2344]
123.29±61.62 134.05±64.33
1.0853
[1.0239–1.1504]
AUCinf,ss (ng·h/mL) 95.58±35.58 115.22±81.21
1.1206
[1.0120–1.2409]
137.80±66.16 149.30±70.21
1.0807
[1.0230–1.1417]
t1/2 (h) 7.59±2.13 8.29±3.36 10.46±3.52 10.90±4.09
CLss/F (L/h) 500.36±169.08 464.02±188.28 385.71±143.68 358.38±143.77
Vdss/F (L) 5456.98±2470.39 5265.92±2681.65 5862.83±2844.59 5445.70±2688.39
Jungsin Park, et al.
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Atorvastatin and ezetimibe interaction
Table 3. Pharmacokinetic parameters of total ezetimibe and free ezetimibe
*Median (min-max). GMR, geometric mean ratio; CI, confidence interval. Treatment B, ezetimibe 10 mg once daily for seven days; treatment C, co-
administration of atorvastatin 40 mg and ezetimibe 10 mg once daily for seven days; Tmax, time to reach maximum plasma concentration; Cmax,ss, 
maximum plasma concentration at steady state; AUCτ,ss, area under the plasma concentration-time curve within a dosing interval at steady state; 
AUCinf,ss, area under the plasma concentration-time curve from dosing time extrapolated to infinity at steady state; t1/2, elimination half-life; CLss/F, 
apparent clearance; Vdss/F, apparent volume of distribution.
Parameters
Total ezetimibe Free ezetimibe
Treatment B Treatment C GMR [90% CI] Treatment B Treatment C GMR [90% CI]
N 32 32 32 32 32 32
Tmax (h)* 1.00 (0.50−3.00) 0.88 (0.50−3.00) 5.00 (0.50−12.00) 1.13 (0.50−5.00)
Cmax,ss (ng/mL) 73.88±27.06 73.44±24.96
1.0005
[0.9227–1.0849]
6.11±2.50 10.95±5.29
1.7871
[1.5651–2.0406]
AUCτ,ss (ng·h/mL) 534.27±212.04 535.28±196.64
1.0176
[0.9465–1.0941]
71.65±27.68 91.25±31.19
1.2979
[1.1888–1.4170]
AUCinf,ss (ng·h/mL) 957.59±460.09 970.70±403.77
1.0359
[0.9569–1.1213]
142.81±69.95 155.14±57.13
1.1548
[1.0340–1.2896]
t1/2 (h) 21.06±8.96 26.80±19.47 22.18±15.96 19.33±11.64
CLss/F (L/h) 21.59±8.24 20.77±6.28 159.02±57.53 122.72±42.27
Vdss/F (L) 656.54±359.50 796.71±653.22 4966.17±3851.77 3324.32±2393.97
Figure 3. Plasma concentration-time profiles of total ezetimibe with or without atorvastatin at steady state plotted using (a) linear and (b) log-linear 
scales, and of free ezetimibe (c) linear and (d) log-linear scales. 
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for atorvastatin when administered with and without ezetimibe 
were 1.1087 (0.9799–1.2544) and 1.1154 (1.0079–1.2344), re-
spectively. The corresponding values of 2-hydroxyatorvastatin 
were 1.1147 (1.0197–1.2184) and 1.0853 (1.0239–1.1504).
  The PK parameters and mean plasma concentration-time 
profiles of total and free ezetimibe with or without atorvastatin 
co-administration are presented in Table 3 and Figure 3. The 
Tmax of co-administered free ezetimibe (with atorvastatin) was 
shortened for about 4 h compared with  that of ezetimibe alone. 
GMRs (90% CIs) of Cmax,ss and AUCτ,ss for total ezetimibe when 
it was administered with and without atorvastatin were 1.0005 
(0.9227–1.0849) and 1.0176 (0.9465–1.0941), respectively. The 
corresponding values for free ezetimibe were 1.7871 (1.5651-
2.0406) and 1.2979 (1.1888-1.4170), respectively. The 90% CIs 
for the Cmax,ss and AUCτ,ss of total ezetimibe were within the 
range of 0.8–1.25 (Table 3).
Safety
  In this study, 33 AEs were reported in 19 subjects. All cases 
were mild (30 events) or moderate (three events) and subjects 
recovered without complications. Commonly reported AEs 
were nasopharyngitis (four events) and epistaxis (four events). 
After causality assessment, 13 AE cases (seven subjects), includ-
ing four in group A, three in group B, and six in group C, were 
considered as adverse drug reactions. No clinically significant 
differences were observed among the treatment groups in terms 
of vital signs, physical examination, 12-lead ECGs, and clinical 
laboratory test results.
Discussion
  We conducted a Williams design crossover study to evaluate 
the PK drug interaction between atorvastatin and ezetimibe in 
healthy Korean volunteers. The results of this study indicated 
that the concomitant administration of ezetimibe did not sig-
nificantly affect the PK profile of atorvastatin. Although atorv-
astatin increased the exposure of free ezetimibe, it did not affect 
total ezetimibe exposure. The above results are consistent with 
those of the earlier studies which reported that atorvastatin and 
ezetimibe have no relevant PK interaction.[11,12]
  When co-administered with ezetimibe, the upper 90% CI of 
GMR for the Cmax,ss of atorvastatin slightly deviated from 1.25; 
however, this was not clinically significant considering that it 
is a highly variable drug.[13] Atorvastatin is generally metabo-
lized by CYP3A4, and the resulting metabolite undergoes gluc-
uronidation by uridine 5´-diphosphate-glucuronosyltransferase 
(UGT) 1A1 and 1A3.[6] Similarly, ezetimibe undergoes gluc-
uronidation by UGT1A1, UGT1A3, and UGT2B15. However, 
the PK characteristics of atorvastatin were not affected because 
it is metabolized by several enzymes resulting highly variable 
PK profile.[8] 
  In this study, the absorption pattern of ezetimibe showed 
multiple peaks, as was shown in previous reports.[14,15] Es-
pecially, the second and the third peaks occurred at 5 and 12 
h after administration, thereby overlapping with the fed state. 
This phenomenon is speculated to occur due to a reabsorption 
process through enterohepatic recirculation, a unique PK char-
acteristic of ezetimibe. As found in previous studies, free ezeti-
mibe exhibited a relatively large inter-individual variability in 
Cmax with the coefficient of variation in the range of 34–48%.[16] 
In most subjects, the 2nd peak concentration of free ezetimibe 
was higher than the 1st peak when ezetimibe administered alone 
whereas the 1st peak concentration was the highest when co-
administered with atorvastatin. This is the reason atorvastatin 
seemed to shorten the Tmax of free ezetimibe. Considering the 
complex absorption characteristics of ezetimibe and the limited 
sample size of this exploratory study design, it may be difficult 
to ascertain that increased exposure of free ezetimibe has clini-
cal significance in terms of safety and efficacy.
  Ezetimibe-glucuronide accounts for 80–90% of total ezetimibe 
concentration in the plasma, and its cholesterol-lowering effect 
is about 90% of that of free ezetimibe. Because the 90% CIs of 
GMRs for the AUCτ,ss and Cmax,ss of total ezetimibe (free ezeti-
mibe + ezetimibe-glucuronide), which are considered primary 
PK parameters for the evaluation of bioequivalence or PK drug 
interaction, were in the range of 0.8–1.25, and the two treatment 
groups showed no significant differences in safety profiles, ator-
vastatin was considered to have no significant clinical impact on 
the PK properties of ezetimibe.
  Atorvastatin and ezetimibe showed similar PK and safety pro-
files when administered alone or in combination. Therefore, it 
can be concluded that the PK interaction between the two drugs 
is not clinically significant in healthy Korean volunteers.
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